NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition
Executive Summary
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.
You may also be interested in...
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.